{"filings":[{"id":1776200,"accession_number":"0001214659-26-008772","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2026-07-21T20:30:22+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alzamend Neuro announces death of director Lynne Fahey McGrath on July 20, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Lynne Fahey McGrath, a director of Alzamend Neuro, passed away on July 20, 2026.","She served on the Board since the company's IPO in June 2021.","Chairman William B. Horne expressed condolences and highlighted her contributions and insights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94620,"accession_number":"0001214659-26-004806","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Alzamend Neuro annual meeting: all proposals pass, including reverse stock split up to 1:10","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected, including William B. Horne, Milton C. Ault III, Stephan Jackman, Henry C. Nisser, Mark Gustafson, Lynne F. McGrath, Jeffrey Oram.","Shareholders approved reverse stock split (Proposal 6): ratio 1:2 to 1:10, board discretion, before April 16, 2027. Vote: 1,150,722 for, 445,185 against.","Ratification of Haskell & White LLP as independent auditor (Proposal 2): 1,454,276 for, 114,748 against, no broker non-votes.","Advisory vote on executive compensation (Proposal 3) passed: 276,241 for, 124,274 against, with 1,185,412 broker non-votes.","2025 Stock Incentive Plan (Proposal 4) and equity issuance approval (Proposal 5) also passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107131,"accession_number":"0001214659-26-003620","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Alzamend Neuro receives Nasdaq deficiency notice for stockholders' equity below $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity reported at ~$2.2M as of Jan 31, 2026, below Nasdaq's $2.5M minimum requirement for continued listing.","Company has until May 4, 2026 to submit a plan to regain compliance; if accepted, Nasdaq may grant up to 180 days (to Sept 16, 2026).","Common stock continues trading on Nasdaq under symbol 'ALZN' with no immediate effect on listing.","Company is evaluating actions to regain compliance; no assurance plan will be accepted or compliance achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107130,"accession_number":"0001214659-26-002932","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Alzamend Neuro enters $3M at-the-market equity agreement with Ascendiant Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $3.0M in common stock may be sold periodically via ATM offering with sole agent Ascendiant Capital Markets.","Sales occur under effective shelf registration statement (Form S-3, File No. 333-273610) from August 2023.","Company controls timing, price, and volume; agent uses commercially reasonable efforts with no minimum commitment.","Common stock trades on Nasdaq under ALZN; shares sold will be freely tradable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123470,"accession_number":"0001214659-25-016885","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alzamend Neuro director Andrew H. Woo, M.D., Ph.D. passed away on Nov. 14, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew H. Woo served as a director since the company's IPO in June 2021.","William B. Horne, Chairman, expressed condolences; Woo is succeeded by no replacement yet.","No other material events reported; financial statements not affected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123469,"accession_number":"0001214659-25-014950","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Alzamend Neuro eliminates Series B and Series C convertible preferred stock","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed Certificates of Elimination for Series B and Series C convertible preferred stock with Delaware Secretary of State on October 14, 2025.","The elimination removes all matters set forth in the Certificates of Designations for those preferred stock series from the company's charter.","No other changes to the capital structure, financial terms, or stock trading were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123468,"accession_number":"0001214659-25-014818","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Alzamend Neuro issues 361,743 shares on Series B Preferred conversion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Between Oct 1-8, 2025, 361,743 shares issued upon conversion of ~839.2 Series B Convertible Preferred shares.","Shares issued under Section 4(a)(2) exemption from registration.","As of Oct 8, 2025, total common shares outstanding: 3,801,604.","Conversion increases outstanding share count by roughly 10.5% from prior level."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140143,"accession_number":"0001214659-25-014200","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Alzamend Neuro issues 300,000 shares on conversion of Series B Preferred Stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 300,000 common shares upon conversion of 696 Series B Preferred shares between Sep 17-25, 2025.","Common shares outstanding as of Sep 25, 2025: 3,439,861.","Shares issued in reliance on Section 4(a)(2) exemption; no registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140142,"accession_number":"0001214659-25-011357","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Alzamend Neuro issues 243,429 common shares on conversion of Series B Preferred (Jul 23-30, 2025)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["243,429 common shares issued upon conversion of ~564.76 shares of Series B Convertible Preferred Stock.","Total common outstanding as of July 30, 2025: 3,139,861 shares.","Issuance made in reliance on Section 4(a)(2) exemption from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140141,"accession_number":"0001214659-25-010830","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alzamend Neuro FY2025 cash $3.9M, equity $3.9M; $5M financing completed ahead of schedule","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash of $3.9M at April 30, 2025 vs $0.4M prior year; stockholder equity of $3.9M vs deficit $2.6M.","Net cash from financing activities was $10.4M for FY2025.","Completed $5M private placement in June 2025, months early; investor accelerated purchase of additional $4M preferred stock.","Dosed first patient in May 2025 for AL001 'Lithium in Brain' Phase II studies at Mass General; topline results expected year-end 2025.","ALZN002 immunotherapy trial delayed; actively seeking new CRO after prior CRO terminated in Feb 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140140,"accession_number":"0001214659-25-010209","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Alzamend Neuro eliminates Series A convertible preferred stock via Certificate of Elimination","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Elimination with Delaware Secretary of State on July 9, 2025 to cancel Series A Preferred Stock.","Certificate of Elimination removes all designations for Series A Preferred Stock from the company's charter.","No changes to fiscal year were made despite Item 5.03 title; only preferred stock elimination occurred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157787,"accession_number":"0001214659-25-007204","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Alzamend Neuro announces 1-for-9 reverse stock split effective May 12 to maintain Nasdaq listing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shares outstanding reduce from ~7,208,591 to ~800,954 at 1-for-9 ratio.","Split effective May 12, 2025; trading symbol remains ALZN with new CUSIP 02262M605.","Reverse split aimed at complying with Nasdaq $1.00 minimum bid price requirement.","No fractional shares issued; holders of fractional shares will receive cash payment.","Par value unchanged at $0.0001 per share; all options/warrants proportionally adjusted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157786,"accession_number":"0001214659-25-006405","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Alzamend Neuro stockholders approve reverse stock split and Series C conversion at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected eight directors including William B. Horne, Milton C. Ault III, and others with substantial support; broker non-votes of 2,270,160.","Ratified Haskell & White LLP as independent auditor for fiscal year ending April 30, 2025; 4,255,027 for, 54,999 against.","Approved conversion of Series C Preferred Stock into common and warrants for up to $5M (less 5% discount); 757,391 for, 142,345 against.","Approved reverse stock split at ratio between 1:2 and 1:10, board to set exact ratio by April 24, 2026; 3,252,166 for, 1,077,493 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176156,"accession_number":"0001214659-25-003727","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Alzamend Neuro amends bylaws to lower stockholder quorum to 35%, creates Series C Preferred Stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board reduced quorum for stockholder meetings from majority of outstanding shares to 35%.","Filed Certificate of Designation for Series C Convertible Preferred Stock with Delaware.","Series C issuance part of previously disclosed exchange and purchase agreement with a sophisticated investor.","Exchange of 97.7511 shares of Series A for Series C; up to 500 additional Series C shares to be sold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176155,"accession_number":"0001214659-25-003658","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Alzamend Neuro signs $5M financing with Orchid Finance; exchanges Series A pref for Series C with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanges 97.75 Series A shares for 87.99 Series C shares; cancels existing 640K-share warrants.","Issues up to 500 Series C shares at $9,500 each for total gross proceeds of $5M (net $4.75M after 5% discount).","Series C carries 15% cumulative quarterly dividend, convertible at formula with $0.10 floor; warrants for 1M shares at $0.92125.","Tranche closings through Oct 2025; second tranche of 75 shares ($725K) due Apr 29 or 15 days post- registration effectiveness.","Stockholder approval required for issuances exceeding 19.99% of outstanding; ROFR and participation rights for investor after $712.5K funded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193061,"accession_number":"0001214659-24-020439","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alzamend Neuro reports Q2 fiscal 2025: cash $4.1M, equity $3.8M, five Phase II trials planned in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net cash from financing $8.3M for six months ended Oct 31, 2024; stockholder equity improved to $3.8M from a $2.6M deficit.","Cash increased to $4.1M from $0.4M; total liabilities reduced to $1.3M from $3.2M at April 30, 2024.","Regained Nasdaq compliance; entered $25M preferred stock/warrant agreement and $6.5M ATM facility.","AL001 (lithium cocrystal) to initiate five Phase II trials in 2025 with Mass General for Alzheimer's, BD, MDD, PTSD.","ALZN002 immunotherapy trial resumption planned for 2025 after re-engaging a new CRO."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193060,"accession_number":"0001214659-24-017549","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["7.01","3.01","9.01"],"status":"ready","headline":"Alzamend Neuro regains Nasdaq compliance; avoids delisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received written notice from Nasdaq Hearings Panel on Oct 14, 2024 that it has regained compliance with minimum stockholders' equity rule ($2.5M required).","Had been notified of delisting in March 2024, appealed to Panel, granted extension until Sept 23, 2024.","Entered $25M Series A Convertible Preferred purchase agreement; $8M already funded, additional $2M due in 30 days, $1M monthly through Jan 2026.","CEO Stephan Jackman states strategic plan executed; company intends to initiate five phase II AL001 trials in 2025 with Massachusetts General Hospital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193059,"accession_number":"0001214659-24-017141","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Alzamend Neuro enters ATM offering for up to $6.5M in common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ATM Sales Agreement with Ascendiant Capital Markets for up to $6.5M of common stock.","Shares sold from time to time at market prices; agent receives customary commission.","Prospectus supplement filed Oct 3, 2024; relies on shelf registration statement 333-273610.","ATM offering provides additional capital but dilutes existing shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209438,"accession_number":"0001214659-24-013382","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["7.01","3.01","9.01"],"status":"ready","headline":"Alzamend Neuro regains Nasdaq bid price compliance; MVLS deficiency still pending","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Alzamend on July 30, 2024 that bid price compliance is regained after 10 consecutive days above $1.00.","Minimum Bid Price Requirement was met on July 29, 2024; matter is now closed.","MVLS deficiency remains: Alzamend must demonstrate compliance with $2.5M stockholder equity by September 23, 2024.","Company appealed delisting for MVLS; hearing panel granted extension to Sept 23, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209437,"accession_number":"0001214659-24-012340","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Alzamend Neuro announces 1-for-10 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective July 16, 2024; reduces outstanding shares from ~7.98M to ~798K.","Split aims to meet Nasdaq minimum bid price of $1.00 per share.","No fractional shares; cash payments for fractional shares via Computershare.","Authorized shares and par value ($0.0001) unchanged.","Stockholders authorized split range 1:2 to 1:20 in April; board set 1:10 in June."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209436,"accession_number":"0001214659-24-012079","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Stockholders approve conversion of Series A Preferred Stock for up to $25M financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal approved with 5,356,845 votes for, 79,371 against, 3,043 abstentions; no broker non-votes.","Conversion relates to Securities Purchase Agreement dated May 8, 2024, for total purchase price up to $25,000,000.","Approval required under Nasdaq Rule 5635 for issuance exceeding certain share thresholds.","Special meeting held July 8, 2024; record date May 29, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227457,"accession_number":"0001214659-24-009785","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["7.01","3.01","9.01"],"status":"ready","headline":"Alzamend Neuro gets Nasdaq extension to meet $2.5M equity rule by Sept 23, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel granted continued listing on Capital Market, subject to compliance with Listing Rule 5550(b)(1).","Company must demonstrate stockholder equity of at least $2.5 million on or before September 23, 2024.","Appeal hearing held May 9, 2024; panel decision received May 21, 2024.","CEO Stephan Jackman stated company is implementing its compliance plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227456,"accession_number":"0001214659-24-009345","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Alzamend Neuro furnishes updated investor presentation for May 2024; no specific new disclosures provided","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed under Item 7.01 as a Regulation FD disclosure; presentation furnished as Exhibit 99.1.","Presentation covers therapeutic drugs for Alzheimer's and other neurodegenerative/psychiatric disorders.","No financial data, clinical trial results, or milestones explicitly stated in the filing's exhibit text.","Company uses the presentation in meetings with investors, stockholders, and analysts.","Filing emphasizes forward-looking statements and risks; no material operational changes announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227455,"accession_number":"0001214659-24-008914","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Alzamend Neuro stockholders approve $6 million Series B transaction with Ault Lending","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved issuance of up to 6,000 shares of Series B convertible preferred stock and warrants for 6,000,000 common shares at $6 million total.","Proposal passed with 2,787,961 votes for, 208,270 against, and 49,368 abstentions at the May 13, 2024 adjourned annual meeting.","The transaction is with Ault Lending, LLC per Securities Purchase Agreement dated January 31, 2024.","The approval allows compliance with Nasdaq Listing Rule 5635 for the Series B Transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.15,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227449,"accession_number":"0001214659-24-008833","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K/A","filed_at":"2024-05-10T23:59:59+00:00","items":["1.01","3.02","5.03","7.01","9.01"],"status":"ready","headline":"Alzamend Neuro raises up to $25M via Series A Preferred and warrants; initial $500K closed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $25 million financing via Series A Convertible Preferred Stock and warrants; initial tranche of $500,000 closed May 10, 2024.","Series A Preferred: $10,000 stated value per share, 15% cumulative annual dividend payable quarterly in cash or shares at investor’s option.","Conversion price is the greater of $0.25 floor or the lesser of $1.50 and 80% of the 3-day VWAP; anti-dilution adjustment applies.","Warrants: exercise price $1.25, 5-year term; 800,000 warrant shares issued in initial tranche. Exercise price adjustable for stock splits.","Stockholder approval required for any conversion/warrant exercise exceeding 19.99% of outstanding common shares; proxy statement to be filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227454,"accession_number":"0001214659-24-008706","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Alzamend Neuro enters $25M financing via preferred stock and warrants at 15% dividend","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial $500,000 closing of 50 Series A Preferred shares at $10,000 each; up to $25M total.","Preferred shares convertible at floor $0.25 or 80% of 3-day lowest close (capped at $1.50).","Warrants for up to 20M common shares at $1.25, exercisable for 5 years, subject to adjustment.","15% annual cumulative dividend payable in cash or additional preferred shares at investor's election.","Proceeds to fund additional clinical trials for Alzheimer's, bipolar, MDD, PTSD; closing expected May 10, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227453,"accession_number":"0001214659-24-008699","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Alzamend Neuro dismisses Baker Tilly as auditor, appoints Haskell & White","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed Baker Tilly US, LLP on May 5, 2024; no accounting disagreements.","Baker Tilly's 2023 audit report included a going-concern explanatory paragraph.","Material weakness in internal control over financial reporting existed in FY 2022 and 2023.","Haskell & White LLP appointed as new independent auditor for fiscal year 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227452,"accession_number":"0001214659-24-008531","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Alzamend Neuro terminates ATM equity program after raising ~$1.3M at ~$1.20/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated ATM agreement with Ascendiant Capital Markets effective May 16, 2024.","Sold 1,076,821 shares and raised approximately $1.3 million in gross proceeds (~$1.20 per share).","Company cited limiting uncertainty and unfavorable dilution for stockholders as reason for termination.","No further sales will be made under the ATM facility; all obligations cease upon termination.","Clinical-stage biotech focused on Alzheimer's, bipolar, MDD, and PTSD treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227451,"accession_number":"0001214659-24-008007","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Alzamend Neuro annual meeting results: reverse split approved, Proposal 3 vote adjourned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; Baker Tilly ratified as auditor for FY ending April 30, 2024.","Reverse stock split approved (ratio 1:2 to 1:20, board to set by April 29, 2025).","Proposal 3 (issuance of up to 6M shares to Ault Lending LLC) lacked sufficient votes; meeting adjourned to May 13, 2024 for further voting.","Outstanding shares: 6,849,407 common and 1,220,000 Series B preferred as of March 14, 2024 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227450,"accession_number":"0001214659-24-007877","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Alzamend Neuro raises $400K via convertible preferred and short-term note","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Sold 100 Series B preferred shares and warrants for 100K common shares to Ault Lending for $100K; total $2.1M of $6M facility drawn.","Issued $310K face promissory note (15% interest, $10K OID) to Orchid Finance LLC; matures May 13, 2024.","Note repayment guaranteed by Ault Lending and Milton C. Ault, Vice Chairman of Alzamend.","Proceeds used for working capital; note matures in two weeks, creating near-term repayment risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246324,"accession_number":"0001214659-24-005635","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["1.01","3.01","3.02","9.01"],"status":"ready","headline":"Alzamend Neuro faces Nasdaq delisting over MVLS; sells $780K Series B convertible to affiliate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified ALZN it fails MVLS rule; delisting scheduled for April 4 unless appeal stays it.","Company will appeal to Hearings Panel by April 2; Common Stock continues trading pending decision.","Sold Series B convertible preferred stock and warrants for $780K to Ault Lending (affiliate); aggregate purchases now $2M of $6M available.","Unregistered sale under Section 4(a)(2) exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246323,"accession_number":"0001214659-24-005032","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["1.01","3.03","5.03","9.01"],"status":"ready","headline":"Alzamend Neuro amends warrant and preferred stock designations to ensure equity classification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Entered warrant amendment with Ault Lending LLC to remove language that could prevent equity classification.","Filed Certificate of Amendment to delete liquidation preference sections from Series B Preferred designations.","Both amendments effective March 21, 2024; no other changes to terms.","Aims to align accounting treatment; does not affect holders' economic rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246322,"accession_number":"0001214659-24-004200","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Alzamend Neuro files amended Series B preferred stock designation and eliminates Series A","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed amended and restated certificate of designations for Series B preferred stock on March 1, 2024.","Amendment corrects references from Series A to Series B and clarifies voting rights per Nasdaq rules.","Filed certificate of elimination to remove Series A convertible preferred stock from charter, effective March 1, 2024.","No changes to preferences and rights of Series B beyond the correction and clarification.","All actions are procedural with no financial or operational impact disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246321,"accession_number":"0001214659-24-001777","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["1.01","3.01","3.02","5.03","9.01"],"status":"ready","headline":"Alzamend Neuro raises up to $6M from affiliate, receives Nasdaq bid price deficiency notice","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered up to $6M Series A convertible preferred stock sale to affiliate Ault Lending; initial $1.22M closed via cancellation of prior advances.","Each preferred share ($1,000 stated value) convertible into common at $1.00/share; warrants exercisable at $1.20/share after 6 months, 5-year term.","Nasdaq deficiency notice: common stock bid price below $1.00 for 30 consecutive days; must regain compliance by July 30, 2024.","Company intends to monitor bid price and may evaluate options including reverse stock split; stock continues trading under 'ALZN'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246320,"accession_number":"0001214659-24-000330","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alzamend Neuro appoints founder Milton C. Ault III as Vice Chairman and director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective January 4, 2024; Ault founded the company in 2016 and previously served as Chairman.","Consulting agreement, including compensation, terminated upon appointment.","Ault also serves as Executive Chairman of Ault Alliance, Inc. (NYSE American) and Chairman of Ault Disruptive Technologies Corp. (NYSE).","Compensation will follow the company's standard board compensation policies as disclosed in FY2023 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263758,"accession_number":"0001214659-23-015278","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["7.01","3.01","9.01"],"status":"ready","headline":"Alzamend Neuro regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on Nov 15, 2023 confirming compliance with $1.00 minimum bid price rule.","Bid price closed at or above $1.00 for 10 consecutive trading days through Nov 13, 2023.","Company had been at risk of delisting since January 2023; hearing extended deadline to Nov 15.","Separate MVLS deficiency remains; Alzamend must regain compliance with $35M market value rule by March 25, 2024.","Press release issued November 16, 2023 announcing the compliance notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263757,"accession_number":"0001214659-23-014086","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Alzamend Neuro announces 1-for-15 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-15 ratio effective 12:01 AM ET on October 31, 2023.","Outstanding shares reduce from ~97M to ~6.47M; par value unchanged at $0.0001.","Split intended to regain compliance with Nasdaq $1.00 minimum bid price requirement.","No fractional shares; cash paid in lieu; new CUSIP 02262M407.","Board approved Oct 17, 2023; stockholders authorized at special meeting Sep 29, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280967,"accession_number":"0001214659-23-012864","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["3.01","5.07","9.01"],"status":"ready","headline":"Alzamend Neuro receives Nasdaq MVLS deficiency notice; stockholders approve reverse stock split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on Sep 26, 2023: MVLS below $35M for 30 consecutive business days.","Cure period: 180 days until Mar 25, 2024; need $35M+ MVLS for 10 consecutive days.","Stockholders on Sep 29, 2023 approved reverse split (ratio 1:2 to 1:20) at board discretion.","Vote tally: 58,463,491 for, 9,749,936 against, 44,645 abstain, 1,609,492 broker non-votes.","If compliance not regained by Mar 25, 2024, Nasdaq will delist; no immediate listing impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280966,"accession_number":"0001214659-23-012579","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2023-09-22T23:59:59+00:00","items":["7.01","3.01","9.01"],"status":"ready","headline":"Alzamend Neuro granted Nasdaq extension to Nov 15, 2023; must execute reverse stock split by Nov 1","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel grants extension until Nov 15, 2023 to regain $1.00 minimum bid compliance.","Conditions: obtain stockholder approval for reverse stock split (ratio 1:2 to 1:20) by Sept 29, 2023.","Company must effect reverse stock split by Nov 1, 2023 and then maintain $1.00 closing bid for 10 consecutive business days.","Annual stockholder meeting scheduled for Sept 29, 2023 to approve reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280965,"accession_number":"0001214659-23-012218","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2023-09-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Alzamend Neuro enters ATM equity facility for up to $9.8M with Ascendiant Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sales Agreement with Ascendiant Capital Markets for at-the-market issuance of common stock up to $9.8M.","Shares sold from time to time under effective shelf registration statement (File No. 333-273610) declared effective Aug 10, 2023.","Agent will use commercially reasonable efforts; Company sets parameters like number, time, and minimum price.","Either party may terminate agreement at any time upon written notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280964,"accession_number":"0001214659-23-011418","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2023-08-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alzamend Neuro to use X and LinkedIn for material disclosures","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company adopts X (Twitter) @AlzamendNeuro and LinkedIn for public communications.","Cites SEC Release No. 69279 on social media disclosure of material non-public info.","Encourages investors to monitor social media alongside website, SEC filings, and press releases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280963,"accession_number":"0001214659-23-010804","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Alzamend Neuro receives Nasdaq delisting notice; hearing scheduled for Oct 12","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Alzamend on Aug 1, 2023 it failed to regain compliance with $1 bid price rule.","Company ineligible for second 180-day period due to not meeting $5M stockholders' equity initial listing requirement.","Delisting was scheduled for Aug 10, 2023, but stay granted pending appeal to Nasdaq Hearings Panel.","Hearing set for Oct 12, 2023; common stock continues trading under symbol ALZN during stay.","Company has submitted required appeal by Aug 8, 2023 deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299642,"accession_number":"0001214659-23-008740","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Alzamend Neuro announces positive Phase IIA results for AL001; identifies MTD without need for lithium TDM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase IIA multiple ascending dose study identified MTD of lithium carbonate equivalent 240 mg TID, unlikely to require lithium TDM.","Company plans two Phase II trials for mild-to-moderate Alzheimer's, initiated by Q1 2024.","Plans to file INDs for bipolar disorder, major depressive disorder, and PTSD by end of 2023.","CEO states data supports AL001 as next-gen lithium therapy without TDM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299641,"accession_number":"0001214659-23-006006","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Alzamend Neuro announces 2023 annual meeting voting results; all proposals pass","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors: Horne, Jackman, Nisser, Gustafson, McGrath, Woo, Oram; each received >46.6M votes for.","Advisory vote on executive compensation approved: 48.4M for, 1.3M against.","Say-on-frequency set to every 3 years (39.7M votes for 3 years); next advisory vote in 2026.","Ratification of Baker Tilly US, LLP as auditor for FY ending April 30, 2023 approved: 49.6M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299640,"accession_number":"0001214659-23-005946","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2023-04-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Alzamend Neuro updates investor presentation for April 2023; no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished an updated corporate presentation (Exhibit 99.1) used for investor meetings.","Presentation provides overview of therapeutic drugs for Alzheimer's and other neurodegenerative diseases.","Information furnished under Regulation FD; not deemed filed for SEC or incorporated by reference.","No specific pipeline updates, financial data, or clinical milestones disclosed with this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299639,"accession_number":"0001214659-23-004684","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Alzamend Neuro initiates Phase I/IIA trial of ALZN002 for mild to moderate Alzheimer's dementia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated Phase I/IIA clinical trial of immunotherapy vaccine ALZN002 for mild to moderate Alzheimer's dementia.","Primary goal: determine appropriate dose for Phase IIB trial; Phase IIB expected within 3 months of initial data.","Enrolling 20-30 subjects with mild to moderate morbidity; assesses safety, tolerability, efficacy vs placebo.","CEO states ALZN002 may limit infusions, reduce adverse reactions, and improve cognitive outcomes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319757,"accession_number":"0001214659-23-004102","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Alzamend Neuro completes Phase IIA MAD trial for AL001; topline data due June 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed clinical portion of Phase IIA multiple ascending dose trial for AL001 in Alzheimer's dementia.","AL001 is a novel lithium-delivery ionic cocrystal aiming to improve safety over current lithium treatments.","Topline data from the MAD study expected in June 2023.","Trial evaluated safety, tolerability, and maximum tolerated dose in mild-to-moderate Alzheimer's patients and healthy subjects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319756,"accession_number":"0001214659-23-003896","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alzamend Neuro Q3 net loss widens to $5.4M; cash $7.4M; clinical milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.4M ($0.06/share) vs $2.6M ($0.03/share) a year ago; R&D spend rose to $2.9M.","Cash $7.4M at Jan 31, 2023; expects $14.8M non-dilutive note receivable in Dec 2023.","Phase IIA topline for AL001 (Alzheimer's) expected June 2023; Phase I/IIA for ALZN002 to start March 2023.","Working capital $5.8M; net cash used in operations $6.7M in nine months."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319755,"accession_number":"0001214659-23-001612","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2023-02-03T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Alzamend Neuro receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on Jan 30, 2023 for bid price below $1.00 for 30 consecutive days.","Has 180 calendar days (until July 31, 2023) to regain compliance by closing at $1.00 for 10 consecutive business days.","May request an additional 180-day compliance period if it meets other listing standards.","No immediate effect on listing; common stock continues trading on Nasdaq under symbol ALZN.","Company intends to monitor bid price and evaluate options to regain compliance, but cannot assure success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319754,"accession_number":"0001214659-23-000871","cik":1677077,"company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","form_type":"8-K","filed_at":"2023-01-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Alzamend Neuro updates corporate presentation; no material new details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Alzamend Neuro refreshed its investor presentation for meetings with investors and analysts.","Presentation covers the company's pipeline for Alzheimer's and psychiatric disorders.","No financial results, guidance, or specific clinical milestones were reported in the filing.","The update is a routine disclosure with no identified material changes to the company's strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":4375452.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-01-20T23:59:59+00:00|319754"}